Reversan

Product Description

Reversan is a selective inhibitor of multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp). Increases the sensitivity of MRP1-overexpressing tumor cells (MCF7/VP) to doxorubicin (Cat. No. 2252), vincristine (Cat. No. 1257) and etoposide (Cat. No. 1226) by 3.8-, 14.6- and 11.6-fold respectively. Increases the efficacy of vincristine and etoposide in murine models of neuroblastoma in vivo. Does not sensitize MRP2, MRP3, MRP4 or MRP5 transporters to known substrates.

Solubility

Preparing Stock Solutions for Reversan

The following data is based on the product molecular weight 441.52

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	11.32 mL	56.62 mL	113.25 mL
1 mM	2.26 mL	11.32 mL	22.65 mL
2 mM	1.13 mL	5.66 mL	11.32 mL
10 mM	0.23 mL	1.13 mL	2.26 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Burkhart Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res. 2009 PMID: 19654298